.webp)
The procedure, which takes approximately one hour, offers a promising alternative for patients who have struggled with the debilitating effects of PTC
An Israeli startup, Vflow, has developed a groundbreaking device that could significantly improve the lives of those suffering from pseudotumor cerebri (PTC), also known as idiopathic intracranial hypertension. PTC is a disorder characterized by increased pressure on the brain due to the buildup of blood and cerebrospinal fluid, causing symptoms that mimic those of a brain tumor. This condition can lead to severe headaches, tinnitus, vision problems, and even depression, potentially resulting in blindness if left untreated. It predominantly affects young women and individuals who are overweight.
Traditionally, treatment options for PTC have been limited and often ineffective. However, Vflow's new device aims to alleviate the pressure by expanding the veins in the brain, allowing for proper fluid drainage and symptom relief. This innovative approach addresses the limitations of previous attempts that utilized rigid stents, which often failed to provide the necessary flexibility and adaptability.
The procedure, which takes approximately one hour, offers a promising alternative for patients who have struggled with the debilitating effects of PTC. Vflow is now seeking significant investment to complete clinical trials and bring this potentially life-changing solution to market.
The company recently gained recognition as a finalist in a startup competition hosted by the Be’er Sheva innovation hub Synergy7 and the Merage Israel Foundation. These organizations support technological advancements in the Negev region, focusing on healthcare, cybersecurity, and robotics. Vflow's success in the competition highlights its potential to make a substantial impact in the medical field and improve the quality of life for those affected by PTC.
.webp)
.webp)
